Le Qin

Dr. Le Qin


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LQLe Qin
Le Qin
LSLiang Shi
Liang Shi
YWYu Wang
Yu Wang
HYHaixin Yu
Haixin Yu
ZDZhouyuan Du
Zhouyuan Du
KWKe Wu
Ke Wu
Despite the notable achievements of programmed death 1 (PD-1) antibodies in treating various cancers, the overall efficacy remains limited in the majority of colorectal cancer (CRC) cases. Metabolism reprogramming of tumors inhibits the tricarboxylic acid (TCA) cycle, leading to down-regulation of fumarate hydratase (FH), which is related to poor prognosis in CRC patients. By establishing a tumor-bearing mouse model of CRC with Fh1 expression deficiency, we confirmed that the therapeutic effect of PD-1 antibodies alone was suboptimal in mice with low Fh1 expression, which was improved by combination with a protein invertase subtilisin/kexin 9 (PCSK9) inhibitor. Mechanistically, FH binds to Ras-related nucleoprotein (RAN), which inhibits the nuclear import of the PCSK9 transcription factor SREBF1/2, thus reducing the expression of PCSK9. This leads to increased clonal expansion of CD8+ T cells while the number of Tregs remains unchanged, and the expression of PD-L1 does not change significantly, thus enhancing the immunotherapy response. On the contrary, the expression of PCSK9 increased in CRC cells with low FH expression, which antagonized the effects of immunotherapy. Overall, CRC patients with low FH expression may benefit from combinatorial therapy with PD-1 antibodies and PCSK9 inhibitors to enhance the curative effect.

11 March 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YHYixin Heng
Yixin Heng
MHMudan Huang
Mudan Huang
JXJiaxin Xu
Jiaxin Xu
XWXiaoyu Wu
Xiaoyu Wu
NHNing Huang
Ning Huang
LQLe Qin
Le Qin
To evaluate the prognostic value of the presence and number of tumor deposits (TDs) and the combination of TDs and number of positive lymph nodes (PLNs) in patients undergoing colorectal cancer (CRC) surgery, and to modify N staging. The clinical data of 1470 patients with stage I-IV CRC who underwent surgery in Wuhan Union Hospital from February 2014 to May 2018 were collected. The optimal cutoff value for TD + PLNs was obtained using X-tile software, and patients were regrouped accordingly. Cox univariate and multivariate analysis were used to screen the factors affecting the prognosis of patients. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to evaluate the predictive ability of independent prognostic factors for overall survival (OS) and disease-free survival (DFS) of patients. The presence of TD was associated with poor OS (HR = 2.478, 95%CI: 1.794–3.422, P<0.001) and DFS (HR = 2.516, 95%Cl: 1.874–3.377, P<0.001). Combined with TD and PLNs, a total of 128 of 395 N1 patients were reclassified re-staged as N2(TD + PLNs ≥ 3), which had a worse prognosis than those diagnosed with N1. Compared with Tumor Node Metastasis stage and TD number, the multivariate model constructed using independent prognostic factors showed better predictive power for OS (AUC:0.769 vs. 0.681 vs. 0.650) and DFS (AUC:0.757 vs. 0.702 vs. 0.650). TD significantly affects the long-term prognosis of CRC patients. Combining TD and PLNs to redefine the tumor staging of CRC patients can improve the accuracy of long-term prognosis of surgical patients.

18 August 2017 in Open Medicine
Verified
Journal Article
Open access
PDF file
LQLe Qin
Le Qin
NJNiu Jianhua
Niu Jianhua
XYXi Yu
Xi Yu
HJHe Jiageng
He Jiageng
MUMulati
Mulati
ObjectiveTo evaluate miR-25 expression in serum of gastric cancer (GC) patients and whether it can be a potential biomarker for GC diagnosis.MethodsForty one pathology confirmed GC patients and 41 healthy controls were included in this study. 10 mL peripheral venous blood were collected from GC patients and healthy controls. miR-25 relative expression and CA19-9 level in serum of GC patients and healthy controls were measured by real-time reverse transcription quantitative polymerase chain reaction (RT-qPCR) and enzyme linked immunosorbent assay (ELISA), respectively. The diagnostic sensitivity, specificity and receiver operating characteristic (ROC) curve of serum miR-25 and CA19-9 were calculated by STATA11.0 software.ResultsThe relative expression of miR-25 was 0.47±0.53 and 0.05±0.36 in serum of GC patients and healthy controls respectively with significant statistical difference (PConclusionAccording to our present study, serum miR-25 was elevated in GC patients which may serve as a diagnostic biomarker for GC.

7 July 2026 in BMC Medical Imaging
Verified
Journal Article
Open access
ZLZhihao Liu
Zhihao Liu
MSMingming Song
Mingming Song
YHYixin Heng
Yixin Heng
TNTong Nie
Tong Nie
JXJiaxin Xu
Jiaxin Xu
LQLe Qin
Le Qin
In colorectal cancer (CRC) patients, body composition (BC) has been recognized as a patient-specific imaging biomarker associated with prognosis. This study aims to construct a joint prediction model based on computed tomography (CT) quantitative body composition and clinical parameters using the Least Absolute Shrinkage and Selection Operator (LASSO) regression model and evaluate its prognostic value in patients undergoing curative surgery for CRC. This multicenter retrospective study analyzed 377 CRC patients who underwent surgical resection from 2017 to 2022. The cohort was split into a training set and a validation set. CT images at the L3 and umbilical levels within 3 months pre-surgery were used to quantify body composition. LASSO regression and COX proportional hazard regression identified independent prognostic factors and developed nomogram prediction models. Model performance was assessed using C-index, receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA), and external validation. LASSO regression identified 7 clinical indicators strongly associated with OS and DFS, respectively. Nomogram prediction models were then created incorporating body composition indicators. ROC curves showed the area under the curve (AUC) of 0.915 and 0.882 for 5 years OS and DFS, respectively. The combined model significantly outperformed TNM staging alone, with AUCs of 0.915 vs. 0.788 for 5 years OS in the training set, and 0.910 vs. 0.735 in the validation set. Calibration and DCA curves indicated strong predictive ability and clinical effectiveness. The combined prediction model based on CT-quantified body composition and clinical indicators effectively predicts CRC prognosis, outperforming the single TNM stage model. Retrospective study, not applicable.